NY-SERMO
1.12.2022 15:06:35 CET | Business Wire | Press release
Timed to World AIDS Day, Sermo, a physician-first online community and leader in global HCP insights, released a new survey that found 46% of general care physicians including PCPs, OB-GYNs, and pediatric physicians, reported they feel they do not have enough knowledge about currently approved PrEP medication options to prescribe them to patients. Whereas 98% of infectious disease specialists reported they felt they have enough knowledge about PrEP medications signaling a need for further education from industry stakeholders for noninfectious disease specialists. An important area of opportunity as patients who are likely good candidates for PrEP often go to a PCP instead of seeking out an infectious disease specialist.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221201005355/en/
The cost of PrEP continues to be a driving factor for patients’ decision to decline treatment in the U.S. as reported by 26% of surveyed physicians. However, PrEP is fully covered in most instances when a patient has private insurance, highlighting another opportunity to further educate patients and providers via patient support and financial assistance programs. Despite PrEP private insurance coverage, young adults 26 years old and under face insurance barriers to accessing PrEP. 23% of surveyed physicians said they don’t know of any resources to help patients on their parent's insurance who want to access PrEP but don’t want their parents to find out. This number declined to 16% when surveying just infectious disease specialists, suggesting an area of opportunity for wider outreach among patient support and financial assistance programs to help this patient population.
Concerns about the cost being the driving factor for patients declining PrEP are lower in Europe than in the U.S. When comparing physician experiences, cost was the number one driver of patients declining PrEP treatment compared to the number three reason in the EU5. The rest of the world followed the U.S. sentiment of cost being the leading reason patients decline PrEP. In Europe, physicians reported the top reason patients declined PrEP treatment is planning to take other preventative measures (27%), followed by stigma (24%), and then cost (20%).
PrEP Adoption Faces Challenges on Multiple Fronts Beyond Cost and Education:
- PrEP isn’t top-of-mind for most patients: only 16% of surveyed physicians reported that patients often proactively asked them for PrEP.
- Patients struggle to maintain adherence to PrEP: 70% of surveyed physicians reported that patients often or sometimes have a hard time adhering to the once-a-day pill schedule of taking PrEP.
- Misinformation about how PrEP works persists as 49% of surveyed physicians reported hearing misinformation about the treatment from patients in their practices.
- When asked the most common misinformation they hear in their practices, PrEP is only for men who have sex with other men is what they heard most often as reported by 63% of physicians. This is in contradiction with the reality that an average of 22% of new HIV diagnoses each year are from heterosexual contact.
“HIV is 100% preventable. Education for both providers and patients is critical in making more progress against the HIV/AIDS epidemic,” says Dr. Claudia Martorell, an Infectious Disease Specialist and Sermo Medical Advisory Board Member. “Education, along with improved insurance coverage, increased medication awareness, better access for at-risk populations, and decreasing stigma around HIV infection all support our ability to do a better job in ending the epidemic.”
Cost & Adherence Keep HIV Patients From Successful Treatment Regiments:
Similar to concerns about the cost of PrEP, affordability is the key treatment attribute that is most important to physicians when recommending an HIV medication to a patient (17%) followed by fewer side effects (15%), and less medication to take each day (13%). In addition, physicians reported adherence is another key barrier to HIV treatment as more than half (56%) of physicians reported that patients they are treating for HIV/AIDS have a difficult time following a strict medication adherence program. Interest in longer-lasting injectable medications is likely to be high among HIV patients, as 48% of surveyed physicians reported that patients simply forgetting to take their medication is the top reason patients didn’t adhere to treatment plans. Multidrug-resistant HIV is also a huge concern for physicians as nearly half (43%) reported treating patients with these issues.
This survey was fielded as part of Sermo’s ongoing Barometer survey. The survey included more than 600 global physicians who were surveyed between November 2nd - 14th, 2022. To explore more findings, visit app.sermo.com/barometer.
About Sermo:
Sermo turns physician experience, expertise, and observations into actionable insights for the global healthcare community. Engaging with more than 1.3 million HCPs across 150 countries, the company provides physicians with a social platform and unique community that fosters impactful peer-to-peer collaboration & discussions about issues that are important to them and their patients. Sermo offers on-demand access to physicians via a suite of proprietary technology to provide business intelligence that benefits pharmaceutical, healthcare partners, and the medical community at large. To learn more, visit www.sermo.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221201005355/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Holiday Data From Xsolla Shows Players Are Shopping, Gifting, and Choosing Brands Inside Video Games16.11.2026 18:00:00 CET | Press release
New Survey of More Than 4,000 Players Finds 78% Play More During the Holidays and 82.5% Would Watch a Rewarded Ad in Exchange for a Bonus Offer Xsolla (USA), Inc., a global commerce company, today announced a new data and insights report on how players shop, spend, and respond to brands during the holiday season. Titled “Why Video Games Belong in Your Holiday Commerce Strategy,” the report draws on direct answers from more than 4,000 players, gathered through opt-in rewarded surveys on Xsolla Offerwall. Players chose to take part and received a reward for sharing, which makes the data first-party and consent-based. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111104582/en/ Graphic: Xsolla The research builds on the conversation Xsolla opened at Advertising Week New York 2026 about how brands can reach players in more ways through video games. Combined with Xsolla’s insights into in-game purchasing behavior across an aud
The Rock-It Company Opens New Regional Office in Nashville16.11.2026 17:00:00 CET | Press release
The expansion demonstrates The Rock-It Company’s dedication to the iconic live music market and opens a new centralized hub that connects live events and luxury goods in a fast-growing region. The Rock-It Company, a global leader in live events and luxury goods logistics, announced the opening of a new regional office in Nashville, Tennessee, reinforcing its presence in one of the world's most important live music and cultural markets. The Nashville office brings together the full Rock-It platform with dedicated offices for Rock-It Cargo, Rock-It Sports, CARS by Rock-It and DIETL by Rock-It, serving as a regional hub for the company's broader portfolio of specialty logistics offerings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116286387/en/ The Rock-It Company office in Nashville, Tennessee “Nashville has been a central part of our business for decades, and we see tremendous opportunity to continue building on that f
IQM Supports NVIDIA’s Work to Make Quantum Computers Schedulable in Slurm16.11.2026 17:00:00 CET | Press release
IQM quantum computers already run at leading supercomputing centers, including Oak Ridge National Laboratory (ORNL), VTT Technical Research Centre of Finland, the Leibniz Supercomputing Centre (LRZ) and CINECA, with users reaching them through Slurm. IQM supports NVIDIA’s investment in making quantum processors a schedulable resource in supercomputing centers by integrating IQM quantum computers with Slurm. IQM’s partner MQSC (Munich Quantum Software Company) has demonstrated the MQSC Orchestrator scheduling IQM systems through the new Slurm capability. IQM Quantum Computers (Nasdaq: IQMX), a global leader in superconducting quantum computers, today announced at SC26 in Chicago its support for NVIDIA’s investment in making quantum processing units (QPUs) a schedulable resource in the Slurm workload manager by integrating IQM quantum computers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116814640/en/ NVIDIA is making q
What Our Pupils Reveal: MindMetrix Joins Wyss Geneva to Bring Eye-Based Biofeedback to Mental Health16.11.2026 15:45:00 CET | Press release
We are proud to welcome MindMetrix AG as one of the newest Wyss Geneva ventures. Born out of research at ETH Zurich’s Neural Control of Movement Lab, MindMetrix is a neurotechnology company that reads the brain’s arousal system through the eyes and turns it into live biofeedback, so people can see, and learn to regulate, their own mental state. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116303495/en/ MindMetrix’s myflow platform turns pupil-based measurements into live biofeedback, with each user’s training sessions and progress shown in a dashboard. Image: MindMetrix The mind is still assessed mostly through questionnaires and self-report, with no objective, real-time measure of brain activity. The size of our pupils changes with the brain’s arousal center, a tiny region deep in the brainstem that is otherwise hard to observe without a brain scan. MindMetrix uses pupillometry to read that signal and turn it into live
Factbird Launches Visual Intelligence and Factbird MCP: AI That Sees the Shop Floor and Connects to Any AI Assistant16.11.2026 15:39:00 CET | Press release
Two new AI capabilities, available now. Visual Intelligence turns camera footage into production data. Factbird MCP gives AI assistants direct access to production data in Factbird. Today, Factbird announces the launch of two new AI capabilities. Visual Intelligence uses cameras and AI to measure what sensors and PLCs miss. Factbird MCP lets AI assistants such as Claude, ChatGPT, and Microsoft Copilot work directly with production data in Factbird. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261113769016/en/ Factbird Visual Intelligence tracking a bottling line in real time, showing filler and shrink wrapper status, line speed of 72 bottles per minute, and operator activity around the line. (AI-generated illustration) The losses that are hardest to explain happen around the machine. A station waits for material. A manual task runs long on the night shift. Each one costs a few minutes, and over a year they add up to real c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
